NCT04375267 2026-04-14
LuPARP
Vastra Gotaland Region
Phase 1 Completed
Clinical Trials
157 trialsNCT05361668 2026-03-19
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Crinetics Pharmaceuticals Inc.
Phase 2 Completed
NCT02402920 2026-03-10
Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT04362436 2026-01-14
ArTisaN
Imperial College London
Phase 2 Completed
NCT03290079 2025-12-22
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03217097 2025-11-21
MGMT-NET
Hospices Civils de Lyon
Phase NA Completed
NCT03910660 2025-10-20
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
BioXcel Therapeutics Inc
Phase 1/2 Completed
NCT05077384 2025-09-16
Open-label Study of Surufatinib in Japanese Patients
Hutchmed
Phase 1/2 Completed
NCT05017662 2025-09-04
A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072
Ariceum Therapeutics GmbH
Phase NA Completed
NCT02678780 2025-07-24
TALENT
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT02611024 2025-07-09
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
Phase 1/2 Completed
NCT01673906 2025-06-24
68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours
Azienda USL Reggio Emilia - IRCCS
Phase 2 Completed
NCT02279433 2025-06-24
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
Nuvation Bio Inc.
Phase 1 Completed
NCT04400474 2025-06-19
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT03037385 2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2 Completed
NCT02840149 2025-05-15
SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors
Jewish General Hospital
Phase 3 Completed
NCT02246127 2025-05-11
SEQTOR
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Completed
NCT03289741 2025-05-09
A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide
Memorial Sloan Kettering Cancer Center
Phase 4 Completed
NCT06456723 2025-05-01
FETONET
Imperial College London
Phase 1/2 Completed
NCT02348749 2025-03-19
18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
NCT04438304 2025-02-12
A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)
Clarity Pharmaceuticals Ltd
Phase 2 Completed
NCT01638533 2025-02-07
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed
NCT05680675 2025-02-06
Dual-Tracer Theranostic PET
University of Utah
Phase NA Completed
NCT02691078 2025-02-04
Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors
Latin American Cooperative Oncology Group
Phase 2 Completed
NCT04197310 2025-01-31
Cabozantinib and Nivolumab for Carcinoid Tumors
Dana-Farber Cancer Institute
Phase 2 Completed
NCT04524442 2025-01-24
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
Advanced Accelerator Applications
Phase 4 Completed
NCT02736500 2025-01-13
LuX
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 1/2 Completed
NCT03980925 2025-01-13
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT04510311 2025-01-10
Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors
University of Michigan Rogel Cancer Center
Phase EARLY_PHASE1 Completed
NCT03095274 2025-01-09
DUNE
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT02724540 2025-01-06
Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT05255133 2025-01-06
Liquid-NET
Universiteit Antwerpen
Phase NA Completed
NCT03278379 2024-12-24
NET-002
Sunnybrook Health Sciences Centre
Phase 2 Completed
NCT03034200 2024-11-26
Phase 2 Study of ONC201 in Neuroendocrine Tumors
Case Comprehensive Cancer Center
Phase 2 Completed
NCT03070301 2024-10-10
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01794793 2024-10-01
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
RECORDATI GROUP
Phase 4 Completed
NCT01678664 2024-09-25
EVACEL
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT06570174 2024-08-26
Oral Protein Supplements for Nutritional and Quality of Life Improvement After Pancreatic Resection in Elderly Patients
Yonsei University
Phase NA Completed
NCT02923934 2024-07-24
A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
Olivia Newton-John Cancer Research Institute
Phase 2 Completed
NCT01873248 2024-07-19
Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective
Jonsson Comprehensive Cancer Center
Phase EARLY_PHASE1 Completed
NCT03288402 2024-06-20
DIB-NET
University Hospitals Coventry and Warwickshire NHS Trust
Phase NA Completed
NCT01849523 2024-05-06
WIN
University Medical Center Groningen
Phase NA Completed
NCT02472678 2024-05-06
WIN
University Medical Center Groningen
Phase NA Completed
NCT02481804 2024-05-06
DIVIT-pilot
University Medical Center Groningen
Phase NA Completed
NCT03143946 2024-05-06
DIVIT Study Diet and Vitamin Supplementation in Patients With a Neuroendocrine Tumor
University Medical Center Groningen
Phase NA Completed
NCT03870399 2024-05-06
HORMONET
AC Camargo Cancer Center
Phase 2 Completed
NCT03834701 2024-02-13
RAPNEN
Catholic University of the Sacred Heart
Phase NA Completed
NCT03873870 2024-01-17
68Ga-DOTATATE PET for Management of Neuroendocrine Tumors
University Health Network, Toronto
Phase NA Completed
NCT02399215 2023-12-26
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Roswell Park Cancer Institute
Phase 2 Completed